Navigation Links
Oculus Innovative Sciences Microcyn Technology Presented in Poster,at European Wound Management Association Conference

pharmaceutical company that develops, manufactures and markets a family of Microcyn(R) Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus' platform technology, called Microcyn, is a non-irritating oxychlorine compound designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus' principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V. Our website is www.oculusis.com.

Forward-Looking Statements

Except for historical information herein, the matters set forth in this press release are forward-looking within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are identified by the use of words such as "intended," "reduce," "reduction," and "designed," among others. These forward-looking statements are based on Oculus Innovative Sciences, Inc.'s current expectations. Investors are cautioned that such forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company's business including risks inherent in the development and commercialization of potential products, the risk that scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, the Company's future capital needs, and its ability to obtain additional funding and other risks detailed from time to time in the Company's filings with the Securities and Exchange Commission including the quarterly report on Form 10-Q for the quarter ended December 31, 2006. Oculus Innovative Sciences disclaims any obligation to update these forward-looking statements.

Oculus and Microcyn are trademarks or regis
'"/>




Page: 1 2 3

Related medicine technology :

1. Next Safety, Inc.s Innovative Drug Delivery System Will Replace Cigarettes and Significantly Advance Pulmonary Medication Delivery
2. Innovative Cancer Drug MabThera Again Shown To Improve Survival Rates In Patients With Lymphoma
3. DNA Therapeutics Reports a Novel Mechanism of Action and a Biomarker of its Lead Molecule Dbait That Open an Innovative Pathway-Targeting in Molecular Cancer Therapy
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. YM BioSciences Announces Preclinical Data Confirming Nimotuzumab Binds to the EGF Receptor and Potentiates Radiotherapy
6. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
7. Advanced Life Sciences Announces Supplemental Efficacy Data from First Pivotal Phase 3 Pneumonia Clinical Trial
8. Advanced Life Sciences to Host Conference Call to Discuss Data From Cethromycins First of Two Phase 3 Pneumonia Trials
9. Sangamo BioSciences Announces Presentation of Phase 1 ZFP Therapeutic Data at American Diabetes Association Meeting
10. Answerthink and LORENZ Life Sciences Group Announce Strategic Alliance for the SAP Life Science Industry
11. Geron Corp. Licensee TA Sciences Announces Landmark 7/07/07 Teleconference to Answer Questions About TA-65, Their Telomerase Activator With Proven Age Management Benefits
Post Your Comments:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly ... and painless for patients to self-inject prescription drugs in the ... including cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... grow to $220B by 2018, according to analysts.   Many of ...
(Date:1/14/2014)... HILLS, Calif. , Jan. 14, 2014 The Brandeis Medical ... Los Angeles a premier and affordable laser tattoo removal ... special. Dr. Brandeis, focus is in providing high quality cosmetic services ... all patients. " Southern California has ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... SOUTHAMPTON, England, March 24 , ... Completes Phase I Dosing , ... medical needs, announces further clinical trial progress with its ... hypertrophy (BPH) and VA111913 for dysmenorrhoea. The Phase IIa,trial ...
... today announced positive results from a Phase 1 trial ... in vitro anti-pseudomonal activity. The results from ... well tolerated, with a clinical and laboratory safety profile ... toxicity was observed, even at the highest dose regimen ...
Cached Medicine Technology:Vantia Therapeutics' Pipeline Continues to Mature 2Vantia Therapeutics' Pipeline Continues to Mature 3Vantia Therapeutics' Pipeline Continues to Mature 4Calixa Therapeutics Announces Positive Phase 1 Results for CXA-101, a Novel Intravenous Cephalosporin Antibiotic with Excellent Anti-Pseudomonal Activity 2
(Date:4/22/2014)... recently FDA-approved device has been shown to reduce seizures ... 50 percent. When coupled with an innovative electrode placement ... facilitated the complete elimination of seizures in nearly half ... clinical trials. , That,s good news for a large ... living with epilepsy whose seizures can,t be controlled with ...
(Date:4/22/2014)... Approximately 15 percent of all lung cancers are ... and often develop resistance to chemotherapy. However, researchers ... revealed new insights into the mechanisms leading to ... , Chemotherapies work primarily by mediating B-cell ... for regulating cell death. Depending on their function, ...
(Date:4/22/2014)... Working with mice and rabbits, Johns Hopkins scientists have ... and breakdown, successfully preventing the development of atherosclerosis, the ... number-one cause of death among humans. The condition develops ... renders them stiff, narrowed and hardened, greatly reducing their ... and the brain. , In a series of experiments, ...
(Date:4/22/2014)... massive health care spending, a new RAND study concludes ... incentivize pharmaceutical companies and device makers to develop products ... medical technologies and their use, a new study suggests ... medical devices get created in the first place. The ... as little loss of health as possible and to ...
(Date:4/22/2014)... Lab researchers have demonstrated the first size-based form ... the membranes of living cells. This unique physical ... information critical to whether a cell lives or ... be obtained through conventional microscopy. , "We,ve developed ... means to both probe and manipulate membrane assemblies, ...
Breaking Medicine News(10 mins):Health News:Newly approved brain stimulator offers hope for individuals with uncontrolled epilepsy 2Health News:Scientists pinpoint protein that could improve small cell lung cancer therapies 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4Health News:US medical innovation needs smarter incentives to cut health spending, study finds 2Health News:US medical innovation needs smarter incentives to cut health spending, study finds 3Health News:First size-based chromatography technique for the study of livi 2Health News:First size-based chromatography technique for the study of livi 3
... FRIDAY, June 25 (HealthDay News) -- When it comes to ... you see, hear, and maybe even smell influence your assessment. ... the chair you,re sitting on, the mug of coffee you,re ... behavior. In a series of experiments, researchers at ...
... The American Physical Society, a leading organization of ... future energy technologies that will strengthen energy security and ... fuel exploration as evidenced by the BP oil spill. ... in the history of the nation has caused ...
... , FRIDAY, June 25 (HealthDay News) -- It,s a ... prescription vial containing years-old medication or an over-the-counter cold ... unless they,re spring-cleaning, many people don,t bother throwing away ... to the toilet and flush the products away. ...
... of America (GSA) the nation,s largest interdisciplinary organization ... Helene Fung, PhD, of the Chinese University of Hong ... and Paul B. Baltes Foundation Award in Behavioral and ... outstanding early career contributions in behavioral and social gerontology. ...
... By Steven Reinberg HealthDay Reporter , THURSDAY, ... risk of dying from a heart attack, stroke or other ... diabetes in one of every 10 deaths from cardiovascular disease, ... "We have known for decades that people with diabetes are ...
... ... world to its new line of American made e-juice. , ... (PRWEB) June 25, 2010 -- Leading electronic ... comfort for not only its loyal customers, but all electronic cigarette users known as "Vapers" ...
Cached Medicine News:Health News:What You Touch May Make You a 'Softie' or Play 'Hard Ball' 2Health News:What You Touch May Make You a 'Softie' or Play 'Hard Ball' 3Health News:APS urges greater federal investment in energy research 2Health News:Outdated Meds Pose Problems If Kept or Tossed 2Health News:Outdated Meds Pose Problems If Kept or Tossed 3Health News:Fung to receive GSA's 2010 Baltes Foundation Award 2Health News:Diabetes May Double Risk of Heart Attack, Stroke 2Health News:Diabetes May Double Risk of Heart Attack, Stroke 3Health News:Leading Electronic Cigarette Manufacturer Vapure Announces U.S. Made E-Liquid 2
Fine pointed grooved jaws with smooth curve from tip to finger grip style handle. Dull finish....
This forcep was designed to eliminate the occasional tearing of tissue which may occur when grasping the lips of an incision with a traditional. 12 forceps. The rows of blunt teeth are gentle yet pro...
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with 90 degrees, 2 x 3 teeth and tying platform. Serrated handle with polished finish. Most popular size or model....
Medicine Products: